Sandoz will pay $450 million to settle antitrust claims brought by 43 U.S. states and territories over alleged anti-competitive conduct in the generic drug market.
Payments spread over seven years to ease financial impact
The Swiss drugmaker’s U.S. subsidiary will distribute $400 million in installments beginning in 2027, with another $50 million set aside for states that reached earlier settlements. Sandoz stated the agreement includes no admission of wrongdoing.
Legal action began in 2016 when state attorneys general filed lawsuits naming Sandoz and its subsidiary Fougera Pharmaceuticals. The suits accused several generic drug manufacturers of price-fixing and market allocation, practices that raised costs for consumers and government programs.
The case belongs to a larger multidistrict litigation, In re Generic Pharmaceuticals Pricing Antitrust Litigation, overseen by the U.S. District Court for the Eastern District of Pennsylvania. That court has also managed related class actions from direct purchasers and end-payers.
Federal cases already resolved, leaving state claims as final hurdle
Earlier federal allegations tied to the same conduct were settled by Sandoz. In 2020, the company entered a deferred prosecution agreement with the U.S. Department of Justice’s Antitrust Division. The next year, it resolved False Claims Act allegations with the DOJ’s Civil Division, agreeing to a corporate integrity agreement with the Department of Health and Human Services’ Office of Inspector General.
Those federal resolutions left state and private claims as the remaining exposure. The current settlement, combined with earlier deals with direct purchasers, effectively ends Sandoz’s involvement in the litigation.
Related: Law Degrees That Boost Career Prospects
The payment plan—$400 million spread over seven years—shows a strategy pharmaceutical companies use when facing multistate antitrust claims. Spreading payments allows Sandoz to meet obligations without disrupting its financial guidance. The company confirmed the settlements will not affect its 2026 outlook.
For compliance teams at other drug manufacturers, the case demonstrates how state attorneys general have become a key force in enforcing pharmaceutical pricing rules. Even after federal cases conclude, state claims can continue for years, creating a separate legal challenge.
The situation extends beyond Sandoz. The multidistrict litigation remains active against other defendants who haven’t settled, indicating state-level antitrust scrutiny of the generic drug industry will likely persist for years.
Many companies involved in these disputes are part of larger corporate groups with multiple subsidiaries, each carrying its own legal risks. Sandoz’s decision to delay most payments until 2027 highlights how businesses balance legal obligations with financial planning, especially when claims span federal and state jurisdictions.
The settlement carries broader implications. It signals to the generic drug industry that state attorneys general will pursue cases independently, even after federal regulators reach their own agreements. That determination could lead to more litigation, additional settlements, and continued pressure on drug pricing.
Legal teams handling injury claims in pharmaceutical cases may find parallels in how these disputes unfold across different levels of government.
